Jeff Nielson | TalkMarkets | Page 2
Independent Information Services Professional
Contributor's Links: Psychedelic Stock Watch
Jeff Nielson is a business writer from Vancouver, Canada who covers markets and the economy. With an academic background in economics and law, he provides a unique perspective in economic trends and market opportunities. In covering markets, Jeff has worked with over 100 public companies spanning ...more

Articles

Latest Posts
17 to 32 of 89 Posts
<<< 1 2 3 4 ... 6 >>>
Psychedelic Stocks: An Investing Hedge For A Crazy World
As investors look for safety in a crazy world, most traditional hedges are currently high-risk assets. Mental health stocks are a perfect hedge for this crazy world.
Atai IPO Day An Underwhelming Event
The IPO of atai Life Sciences was arguably the most-anticipated event in the emerging psychedelic drug industry. It failed to live up to expectations.
Inflation Capitulation Signals Dollar’s Demise, Gold’s Rise
Western central banks have thrown in the towel when it comes to controlling inflation. But central bankers (and their apologists) don't want you to know this.
Psychedelic Drug Stocks: A Big Healthcare Footprint At A Small Price
Fuelled by hundreds of millions in startup capital, psychedelic drug companies are powering a Revolution in healthcare. But with the sector currently in a trough, investors can still enter at ground-floor prices.
Professional Sports Turn To Psychedelics
Psychedelic drug R&D is rapidly expanding into many of the largest medical treatment markets.
U.S. Hyperinflation Unmasked: BoA Sees ‘Transitory Hyper-Inflation’ Coming
Bank of America created shock-waves with its observation that "transitory hyper-inflation" is coming. Want a bigger shock? There will be nothing "transitory" as this time-bomb detonates.
Why Smaller Psychedelics Companies Should Start Catching Up To The Sector Leaders
Concentration of ownership in psychedelic drug stocks has reached a new extreme. We explain how and why we don't see this trend as being sustainable.
The Next Psychedelic Stock To Uplist On The Nasdaq?
As MindMed Inc makes its long-awaited move to the Nasdaq, the obvious question is: who's next?
Déjà Vu: 2021 Slump In Psychedelic Stocks Mirrors 2020
Charts for most psychedelic drug stocks look terrible in recent weeks. The same was true in the summer of 2020 -- immediately before these stocks exploded higher. Deja vu?
The Mental Health Crisis
Two pandemics are currently afflicting the planet. While our governments focus on the smaller one (COVID-19), the larger one (the Mental Health Crisis) is rapidly spiralling out of control.
Psychedelic Stocks Primed For Atai-MindMed Bounce
It's now looking like the atai Life Sciences IPO and the MindMed uplisting to the Nasdaq could occur within weeks of each other. We point out what that means for investors in psychedelic stocks.
Hard Numbers On The Huge Potential Of Psychedelic Drug Development
Drug development is expensive. It is also extremely lucrative. We take a close look at this revenue potential.
Cashed-Up Psychedelic Stocks Well Prepared For Adverse Market Conditions
Psychedelic stocks are cash-rich and well positioned to explode higher out of the current trough.
The COVID Conundrum For Psychedelic Stocks
The COVID pandemic is (indirectly) making the psychedelic drug industry a much more attractive investment opportunity. The catch? It's also drowning out coverage of this emerging sector.
Traumatic Brain Injury: Six Psychedelics Companies Target $120 Billion Market
The largest single treatment market targeted by psychedelics R&D. Another area where psychedelic drugs have the potential to revolutionize medical treatment.
How Analysts Are Asleep At The Wheel Regarding Psychedelic Stocks
Market analysts missed badly on many of their cannabis stock forecasts. Now these same analysts appear to be asleep at the wheel regarding the potential of psychedelic stocks.
17 to 32 of 89 Posts
<<< 1 2 3 4 ... 6 >>>